Descrizione del progetto
Verso una produzione farmaceutica europea di API più sostenibile
I prodotti farmaceutici comprendono un’ampia varietà di composti chimici progettati per garantire terapie sicure ed efficaci. Le materie prime farmacologicamente attive (API) producono effetti benefici sulla salute dei pazienti. L’obiettivo del progetto TransPharm, finanziato dall’UE, è quello di sviluppare API più sostenibili ed ecologiche che riducano contemporaneamente l’impronta ambientale e la dipendenza da paesi terzi per la loro produzione. TransPharm fornirà strumenti digitali e linee guida basati sull’intelligenza artificiale per lo sviluppo di prodotti farmaceutici e API più ecologici, nonché di modelli per valutarne l’impatto. Il risultato sarà un’industria farmaceutica europea più indipendente e competitiva, in grado di garantire la fornitura tempestiva di prodotti terapeutici sostenibili ed ecologici ai cittadini.
Obiettivo
TransPharm two-track approach focusses on the one hand on the compounds itself by identifying greener and more sustainable-by-design Active Pharmaceutical Ingredients (APIs) and on the other hand reducing the environmental impact and resilience of the manufacturing process by optimizing the synthesis route of new APIs in continuous flow and by proposing greener alternative solvents.
The aim of the project is to (i) analyse and predict flow behaviour and environmental biodegradability of APIs and their synthesis pathways; (ii) identify greener and more sustainable alternatives to pharmaceutical products / APIs of concern; (iii) reduce the footprint and create important shortcuts in synthetic schemes of APIs; and (iv) assess the sustainability of pharmaceuticals over their entire life cycle. To reach the envisaged aims, the project will deliver four toolboxes (consisting of digital tools and guidelines) for the development of greener pharmaceutical products and APIs. These toolboxes will be used to (v) assess the potential to move towards the transition to greener, more agile pharmaceutical production. In addition, TransPharm will elaborate on the business case for sustainable pharmaceutical products or APIs and what is needed to bring them to the market. The project will also make sure that (vi) key project results and knowledge are properly transferred towards targeted stakeholders.
TransPharm?s outcome contribute to a Europe, that is self-sufficient by reducing dependence on API production in third countries; making the EU healthcare industry more competitive, sustainable and reliable, ensuring timely supply of essential medicines from particularly complex or critical supply and distribution chains and positioning EU as a leader in innovative technologies.
Campo scientifico
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- social scienceseconomics and businessbusiness and managementbusiness models
- social scienceseconomics and businesseconomicsproduction economicsproductivity
- social scienceseconomics and businesseconomicssustainable economy
Parole chiave
Programma(i)
Argomento(i)
Meccanismo di finanziamento
HORIZON-RIA - HORIZON Research and Innovation ActionsCoordinatore
9000 Gent
Belgio